Single-Cell RNA Sequencing Unveils CD8+ T Cell Heterogeneity in the Diffuse Large B-cell Lymphoma Microenvironment: A Systematic Review.
Researchers mapped the immune cells that predict CAR-T success in lymphoma, revealing which cell types support remission and which mechanisms help cancers resist treatment.
A PRISMA systematic review of 18 scRNA-seq studies in DLBCL constructed a comprehensive CD8+ T cell exhaustion atlas revealing hierarchical functional subclusters associated with treatment response and resistance. Key findings include Tpex cells as favorable prognostic and therapeutic targets and CD58 pathway loss as a CAR-T resistance mechanism, supporting cell-state-guided precision immunotherapy.
What the study was
- Study design
- Systematic review (PRISMA/PROSPERO; 18 scRNA-seq studies, no meta-analysis)
- Population
- DLBCL patients with tumor samples profiled by single-cell RNA sequencing
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Critical Reviews in Oncology/Hematology
Why it surfaced
PROSPERO-registered systematic review of scRNA-seq data identifying CAR-T resistance biomarkers (CD58) and pre-treatment stratification targets in DLBCL; translational relevance to ongoing CAR-T trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.